BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel
Product News Mar 28, 2018
BD introduces the ability to execute in vitro rapid identification (ID) and antimicrobial susceptibility testing (AST) for meropenem-vaborbactam in a new panel for the BD Phoenix™ Automated Microbiology System, which detects resistance in Enterobacteriaceae, Non-Enterobacteriaceae and most gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus. The BD Phoenix™ offers clinical microbiology laboratories the ability to rapidly and accurately test antimicrobial resistances or susceptibilities. BD’s rapid and reliable results for ID and AST are powered through an oxidation-reduction indicator with turbidity measurement for growth detection, as well as full on-panel antimicrobial concentrations and the BDXpert system for data analysis.